Bee Venom-Based Peptide Conjugate Shrinks Prostate Tumors by Eliminating Cancer-Protecting Immune Cells

Researchers differentiated human THP-1 monocytes into TAMs using tumor-conditioned medium. MEL-dKLA binding specificity was tested with fluorescent-labeled melittin. Functional effects were measured through proliferation, migration, and invasion assays using PC-3 prostate cancer cells. In vivo efficacy was tested in mice bearing TRAMP-C2 prostate tumors, with MEL-dKLA administered every three days. Tumor immune cell composition was analyzed by immunostaining.

Prostate cancer often creates an immunosuppressive microenvironment using tumor-associated macrophages that shield it from immune attack. Rather than targeting cancer cells directly, this peptide conjugate eliminates the immune-suppressing macrophages, allowing the body's own T cells to attack the tumor. This approach represents a fundamentally different strategy in cancer immunotherapy — using peptides to reshape the tumor environment rather than directly kill cancer cells.

Cancer immunotherapy has largely focused on directly activating T cells (with checkpoint inhibitors) or engineering them (with CAR-T cells). This peptide-based approach takes a complementary strategy — removing the immunosuppressive cells that prevent natural immune responses. As the field recognizes the importance of the tumor microenvironment, peptide conjugates that can selectively eliminate specific immune cell populations may become valuable additions to the immunotherapy toolkit.

The mouse model uses subcutaneous tumor implantation, which does not fully replicate human prostate cancer biology or the tumor microenvironment. The study did not test long-term effects, potential toxicity to normal macrophages, or resistance mechanisms. Melittin is derived from bee venom and may have off-target effects at higher doses. Translation to human prostate cancer would require extensive safety and efficacy testing.